Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

core laboratories - CLB

CLB

Close Chg Chg %
18.89 0.08 0.40%

Closed Market

18.96

+0.08 (0.40%)

Volume: 250.23K

Last Updated:

Jan 9, 2026, 3:59 PM EDT

Trade Now

Company Overview: core laboratories - CLB

CLB Key Data

Open

$19.11

 Day Range

18.56 - 19.30

52 Week Range

9.72 - 20.82

 Market Cap

$839.54M

Shares Outstanding

46.56M

 Public Float

45.77M

Beta

1.04

 Rev. Per Employee

N/A

P/E Ratio

26.29

 EPS

$0.69

Yield

22.19%

 Dividend

$0.01

EX-DIVIDEND DATE

Nov 3, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

353.59K

  

CLB Performance

1 Week
 
 11.92%
 
1 Month
 
 15.11%
 
3 Months
 
 83.64%
 
1 Year
 
 5.39%
 
5 Years
 
 -38.77%
 

CLB Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About core laboratories - CLB

Core Laboratories Inc. provides proprietary and patented reservoir description and production enhancement services. It operates through the Reservoir Description and Production Enhancement segments. The Reservoir Description segment engages in petroleum reservoir analysis for energy. The Production Enhancement segment includes services and manufactured products associated with reservoir well completions, perforations, stimulation, production and well abandonment. The company was founded in 1936 and is headquartered in Houston, TX.

CLB At a Glance

Core Laboratories Inc.
6316 Windfern Road
Houston, Texas 77040
Phone 1-713-328-2673 Revenue 523.85M
Industry Oil & Gas Production Net Income 31.40M
Sector Energy Minerals 2024 Sales Growth 2.758%
Fiscal Year-end 12 / 2025 Employees 3,500
View SEC Filings

CLB Valuation

P/E Current 26.292
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 25.855
Price to Sales Ratio 1.576
Price to Book Ratio 3.217
Price to Cash Flow Ratio 14.64
Enterprise Value to EBITDA 15.611
Enterprise Value to Sales 1.894
Total Debt to Enterprise Value 0.182

CLB Efficiency

Revenue/Employee 149,670.857
Income Per Employee 8,971.429
Receivables Turnover 4.113
Total Asset Turnover 0.89

CLB Liquidity

Current Ratio 2.322
Quick Ratio 1.713
Cash Ratio 0.196

CLB Profitability

Gross Margin 16.87
Operating Margin 9.278
Pretax Margin 8.772
Net Margin 5.994
Return on Assets 5.337
Return on Equity 13.171
Return on Total Capital 7.266
Return on Invested Capital 7.375

CLB Capital Structure

Total Debt to Total Equity 71.488
Total Debt to Total Capital 41.687
Total Debt to Total Assets 30.512
Long-Term Debt to Equity 67.246
Long-Term Debt to Total Capital 39.213
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Core Laboratories - CLB

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
470.25M 489.74M 509.79M 523.85M
Sales Growth
-3.49% +4.14% +4.10% +2.76%
Cost of Goods Sold (COGS) incl D&A
386.41M 410.82M 415.74M 435.48M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
18.52M 17.16M 15.78M 14.95M
Depreciation
17.75M 16.48M 15.29M 14.45M
Amortization of Intangibles
762.00K 685.00K 490.00K 504.00K
COGS Growth
-2.33% +6.32% +1.20% +4.75%
Gross Income
83.84M 78.92M 94.05M 88.37M
Gross Income Growth
-8.50% -5.87% +19.17% -6.04%
Gross Profit Margin
+17.83% +16.11% +18.45% +16.87%
2021 2022 2023 2024 5-year trend
SG&A Expense
44.17M 38.12M 40.26M 39.77M
Research & Development
- - - -
-
Other SG&A
44.17M 38.12M 40.26M 39.77M
SGA Growth
+29.79% -13.71% +5.62% -1.21%
Other Operating Expense
- - - -
-
Unusual Expense
(2.24M) (669.00K) 1.69M (6.62M)
EBIT after Unusual Expense
41.90M 41.47M 52.10M 55.23M
Non Operating Income/Expense
3.30M (241.00K) 2.14M 3.09M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
9.15M 11.57M 13.43M 12.37M
Interest Expense Growth
-33.21% +26.42% +16.08% -7.90%
Gross Interest Expense
9.15M 11.57M 13.43M 12.37M
Interest Capitalized
- - - -
-
Pretax Income
36.05M 29.66M 40.82M 45.95M
Pretax Income Growth
+139.48% -17.72% +37.61% +12.58%
Pretax Margin
+7.67% +6.06% +8.01% +8.77%
Income Tax
15.89M 10.30M 4.19M 14.03M
Income Tax - Current - Domestic
9.18M 10.95M 15.25M 13.41M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
6.71M (657.00K) (11.06M) 620.00K
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
20.22M 19.66M 37.03M 32.15M
Minority Interest Expense
492.00K 205.00K 350.00K 753.00K
Net Income
19.73M 19.45M 36.68M 31.40M
Net Income Growth
+120.29% -1.39% +88.53% -14.38%
Net Margin Growth
+4.19% +3.97% +7.19% +5.99%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
19.73M 19.45M 36.68M 31.40M
Preferred Dividends
- - - -
-
Net Income Available to Common
19.73M 19.45M 36.68M 31.40M
EPS (Basic)
0.4288 0.4198 0.7856 0.6695
EPS (Basic) Growth
+119.62% -2.10% +87.14% -14.78%
Basic Shares Outstanding
46.01M 46.33M 46.68M 46.90M
EPS (Diluted)
0.4225 0.4155 0.7717 0.6585
EPS (Diluted) Growth
+119.33% -1.66% +85.73% -14.67%
Diluted Shares Outstanding
46.69M 46.81M 47.52M 47.69M
EBITDA
58.18M 57.96M 69.57M 63.56M
EBITDA Growth
-14.55% -0.38% +20.03% -8.65%
EBITDA Margin
+12.37% +11.84% +13.65% +12.13%

Snapshot

Average Recommendation HOLD Average Target Price 15.333
Number of Ratings 4 Current Quarters Estimate 0.135
FY Report Date 03 / 2026 Current Year's Estimate 0.806
Last Quarter’s Earnings 0.199 Median PE on CY Estimate N/A
Year Ago Earnings 0.738 Next Fiscal Year Estimate 0.992
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 2
Mean Estimate 0.14 0.21 0.81 0.99
High Estimates 0.18 0.25 0.89 1.04
Low Estimate 0.06 0.18 0.73 0.94
Coefficient of Variance 38.52 14.92 8.89 7.42

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 1 1 1
SELL 1 1 1
MEAN Hold Hold Hold

Insider Actions for Core Laboratories - CLB

Date Name Shares Transaction Value
Apr 3, 2025 Kwaku Temeng Director 25,528 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 3, 2025 Katherine Murray Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 3, 2025 Katherine Murray Director 8,069 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 3, 2025 Katherine Murray Director 21,221 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 3, 2025 Martha Z. Carnes Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 3, 2025 Martha Z. Carnes Director 8,069 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 3, 2025 Martha Z. Carnes Director 46,328 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 3, 2025 Kwaku Temeng Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 3, 2025 Kwaku Temeng Director 8,069 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 3, 2025 Curtis V. Anastasio Director 15,736 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 3, 2025 Michael Straughen Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 3, 2025 Michael Straughen Director 29,186 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 3, 2025 Michael Straughen Director 24,552 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.98 per share 367,788.96
Apr 3, 2025 Harvey R. Klingensmith Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 3, 2025 Harvey R. Klingensmith Director 8,069 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 3, 2025 Harvey R. Klingensmith Director 41,962 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 3, 2025 Curtis V. Anastasio Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 3, 2025 Curtis V. Anastasio Director 8,069 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Core Laboratories in the News